Live Breaking News & Updates on Department Of Soft Tissue Bone Sarcoma

Stay updated with breaking news from Department of soft tissue bone sarcoma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Eftilagimod Alpha Novel Triplet Combination is Well Tolerated, Generates CRs in Soft Tissue Sarcoma

Eftilagimod alpha plus radiotherapy and pembrolizumab was safe and displayed initial activity in soft tissue sarcoma. ....

United States , Katarzyna Kozak , Maria Sklodowska Curie National Research Institute Of Oncology , Department Of Soft Tissue Bone Sarcoma , Bone Sarcoma , Eftilagimod Alpha , Soft Tissue Sarcoma , Phase 2 Eftisarc Neo Trial Nct06128863 ,

First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Media Release SYDNEY, AUSTRALIA, July 28, 2023 Immutep Limited , a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today. ....

United States , New South Wales , Maria Sklodowska Curie , Katarzyna Kozak , Chris Basta , Drug Administration , Prevention Division , Corporate Communications , Curie National Research Institute , Globenewswire Inc , American Cancer Society , Department Of Soft Tissue Bone Sarcoma , Immutep Limited , Research Agency , Curie National Research Institute Of Oncology , Cell Research , National Research Institute , Medical Research Agency , Principal Investigators , Bone Sarcoma , Eftilagimod Alpha , Fast Track Designation , States Food , Cancer Clinic , Neck Cancer Clinic , Visceral Surgery ,

Press Release Media Contacts: IB Communications Tel +44 (0)20 89434685 immutep@ibcomms.agency Immutep announces investigator-initiated Phase II trial

Immutep announces investigator-initiated Phase II trial evaluating LAG-3 candidate eftilagimod alpha (efti) in soft tissue sarcoma Expansion of the efti clinical development pipeline with a new Phase II settingEfti Phase II trial awarded EUR 1.5M (AUD 2.2M) in funding as part of the Polish Medical Research Agen. ....

New South Wales , Katarzyna Kozak , Frederic Triebel , Pawel Sobczuk , Marc Voigt , Maria Sklodowska Curie National Research Institute Of Oncology , Research Agency , Curie National Research Institute Of Oncology , Department Of Soft Tissue Bone Sarcoma , Maria Sklodowska Curie National Research Institute , Institute For Drug , Polish Medical Research Agency , Immutep Limited , Material Transfer Agreement , Curie National Research Institute , Polish State Institute , Drug Control , Principal Investigators , Bone Sarcoma , Sklodowska Curie National Research Institute , Medical Oncology Fellow , Co Principal Investigator ,